{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:23:20Z","timestamp":1788481400216,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006556","name":"H\u00f4pitaux de Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004718","name":"Universit\u00e9 de Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtha.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:23:44Z","timestamp":1775809424000},"page":"2567-2578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6427-4699","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"Zordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Zadro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Moulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.04.002_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.04.002_bib2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.002_bib3","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.04.002_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109109","article-title":"The immune thrombocytopenia paradox: should we be concerned about thrombosis in ITP?","volume":"241","author":"Saldanha","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.002_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jth.14446","article-title":"Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia","volume":"17","author":"Adelborg","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.002_bib7","doi-asserted-by":"crossref","first-page":"E181","DOI":"10.1002\/ajh.25127","article-title":"CARMEN investigators group. Cardiovascular risk factors in immune thrombocytopenia adults: results from the CARMEN registry","volume":"93","author":"Moulis","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib8","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/jth.12636","article-title":"Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors","volume":"12","author":"Ruggeri","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.002_bib9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.thromres.2019.04.016","article-title":"Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia \u2013 results from two nationwide cohorts","volume":"178","author":"Ekstrand","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.002_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bjh.17709","article-title":"Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study","volume":"195","author":"Lafaurie","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.17390","article-title":"Thrombosis in immune thrombocytopenia \u2014 current status and future perspectives","volume":"194","author":"Swan","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib14","first-page":"3094","article-title":"Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries","volume":"110","author":"Moulis","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.002_bib15","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.002_bib16","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.002_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.12181","article-title":"Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials","volume":"91","author":"Rodeghiero","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib20","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40264-015-0337-1","article-title":"Signal for thrombosis with eltrombopag and romiplostim: a disproportionality analysis of spontaneous reports within VigiBase\u00ae","volume":"38","author":"Nguyen","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtha.2026.04.002_bib21","first-page":"409","article-title":"VigiBase, the WHO Global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.jtha.2026.04.002_bib22","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.04.002_bib23","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.1002\/ajh.26040","article-title":"High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia","volume":"96","author":"Roumier","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib24","article-title":"EHA2024 Hybrid Congress","volume":"8","author":"Therme","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.jtha.2026.04.002_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","article-title":"French health insurance databases: what interest for medical research?","volume":"36","author":"Moulis","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jtha.2026.04.002_bib26","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug"},{"key":"10.1016\/j.jtha.2026.04.002_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/ejh.12926","article-title":"Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database","volume":"99","author":"Mezaache","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2515\/therapie\/2014056","article-title":"Pharmacoepidemiology of Immune Thrombocytopenia: protocols of FAITH and CARMEN studies","volume":"69","author":"Moulis","year":"2014","journal-title":"Therapie"},{"key":"10.1016\/j.jtha.2026.04.002_bib29","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.002_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics","volume":"58","author":"Schneeweiss","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtha.2026.04.002_bib31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/fcp.12326","article-title":"Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database","volume":"32","author":"Prat","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.04.002_bib32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/fcp.12143","article-title":"Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database","volume":"29","author":"Bezin","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.04.002_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00415-012-6686-0","article-title":"How accurate is the reporting of stroke in hospital discharge data? A pilot validation study using a population-based stroke registry as control","volume":"260","author":"Aboa-Eboul\u00e9","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.jtha.2026.04.002_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000438859","article-title":"Positive predictive value of French hospitalization discharge codes for stroke and transient ischemic attack","volume":"74","author":"Giroud","year":"2015","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jtha.2026.04.002_bib35","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.jtha.2026.04.002_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jtha.2026.04.002_bib37","author":"Godeau"},{"key":"10.1016\/j.jtha.2026.04.002_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson Comorbidity Index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.jtha.2026.04.002_bib39","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jtha.2026.04.002_bib40","article-title":"An introduction to competing risks in epidemiology","volume":"18","author":"S\u00f8rensen","year":"2026","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jtha.2026.04.002_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmpb.2016.03.008","article-title":"Covariate adjustment of cumulative incidence functions for competing risks data using inverse probability of treatment weighting","volume":"129","author":"Neumann","year":"2016","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jtha.2026.04.002_bib42","first-page":"1365","article-title":"Emulating a randomised controlled trial with observational data: an introduction to the target trial framework","volume":"37","author":"Kutcher","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jtha.2026.04.002_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3414\/ME0478","article-title":"Modeling repeated time-to-event health conditions with discontinuous risk intervals: an example of a longitudinal study of functional disability among older persons","volume":"47","author":"Guo","year":"2008","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.jtha.2026.04.002_bib44","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.04.002_bib45","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","article-title":"A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions","volume":"66","author":"Latouche","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtha.2026.04.002_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5886","article-title":"Core concepts in pharmacoepidemiology: time-to-event analysis approaches in pharmacoepidemiology","volume":"33","author":"Rippin","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2026.04.002_bib47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.04.002_bib48","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing E-values","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.jtha.2026.04.002_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12959-023-00509-z","article-title":"Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis","volume":"21","author":"Dong","year":"2023","journal-title":"Thrombosis J"},{"key":"10.1016\/j.jtha.2026.04.002_bib50","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.2021010735","article-title":"Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia","volume":"138","author":"Palandri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.002_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjh.14412","article-title":"Procoagulant profile in patients with immune thrombocytopenia","volume":"175","author":"\u00c1lvarez-Rom\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2019.11.031","article-title":"Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists","volume":"185","author":"Garabet","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.002_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100774","article-title":"Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients","volume":"47","author":"van Dijk","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2026.04.002_bib54","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.jtha.2026.04.002_bib55","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/imj.14269","article-title":"Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study","volume":"49","author":"Le Guenno","year":"2019","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtha.2026.04.002_bib56","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ajh.70192","article-title":"Incidence, characteristics, and management of venous thrombosis in adult patients with immune thrombocytopenia: results from the multicenter, prospective registry CARMEN-France","volume":"101","author":"Therme","year":"2026","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2015.11.001","article-title":"Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis","volume":"15","author":"Moulis","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2026.04.002_bib58","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/ajh.70194","article-title":"Real-world effectiveness and safety of fostamatinib in difficult-to-treat immune thrombocytopenia patients. A prospective, multicenter registry in France","volume":"101","author":"Moulis","year":"2026","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211010875","article-title":"Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib","volume":"12","author":"Cooper","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2026.04.002_bib60","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.2024027336","article-title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study","volume":"145","author":"Kuter","year":"2025","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:43:15Z","timestamp":1785879795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626002187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1538783626002187"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.002","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}